echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The world's first umbilical cord-to-card endothetic stem cell bank operates on a large scale

    The world's first umbilical cord-to-card endothetic stem cell bank operates on a large scale

    • Last Update: 2020-07-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    the world's first interstitial stem cell bank, built by the National Engineering Research Center for Cell Products, has successfully stored nearly 5,000 copies of umbilical cord-filled stem cells in operation for nearly a year and successfully started large-scale operationsThe National Engineering Research Center for Cell Products was approved by the National Development and Reform Commission in 2004 to set up, and Tianjin Ansai Cell Genetic Engineering Co., Ltdas its project legal entity independently undertook the research and development and operation of the centerUnder the leadership of the Director of the Center and Foreign Academician of the French Academy of Medical Sciences, Professor Han Zhongchao, the Center first conquered the cutting-edge technology of isolating cultured inhomogenous stem cells from umbilical cord tissue, invented a patented technology (human placenta, interummy-to-theogenetic stem cell bank and construction methods), and successfully established the world's first interstitial stem cell bank using the patented technologyUsing this patented technology, they also prepared a new stem cell treatment ——— umbilical cord-filled stem cell injectionAnimal experiments have proved that this injection has significant therapeutic effect on a variety ofdiseases caused by aging and injury, such asheartdisease, paralysis caused by nerve damage and immunorejection syndrome after hematopoietic stem cell transplantationIt is understood that the "key technology and industrialization project of stem cell product development" led by the National Engineering Research Center of cell products was recently listed as one of the 20 major projects of independent innovation industrialization identified and implemented in TianjinThe main content is to develop umbilical cord-filling stem cell treatment products and genetically engineered recombinant PF4 and HAPO and other new drugs, breaking through the key technologies of umbilical cord-to-cord hyperstine stem cell separation, large-scale culture and storage(Feng Guoxuan)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.